The FDA has approved Foundayo (orforglipron), the first drug under its new Commissioner's National Priority Voucher pilot program. This weight management medication was approved in just 50 days for adults with obesity or overweight plus weight-related health conditions. Two 72-week clinical trials demonstrated statistically significant weight reduction when combined with diet and exercise. The approval came 294 days ahead of its original January 2027 deadline, highlighting the FDA's commitment to expediting important metabolic health treatments.
